Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Mutat Res. 2011 Feb 15;708(1-2):59–68. doi: 10.1016/j.mrfmmm.2011.02.001

Fig. 3.

Fig. 3

Mili is required for the maintenance of euchromatic marks in MEFs following cisplatin treatment. (A) Mili-WT and KO MEFs were treated with cisplatin for 1 h and further cultured in drug-free medium for indicated time periods. The different marks of euchromatin and heterochromatin were detected using Western blotting. (B) The band intensities were quantitatively assessed by scanning programs, normalized to Histone levels, and the changes of various marks in MEFs were plotted at 1 and 2 h post-treatment (Bars: SD, n=2). *: p < 0.05, **: p < 0.01 compared with their corresponding protein level changes in Mili-WT. (C) Mili-KO MEFs were pretreated with Sodium butyrate for 0.5 h, and then treated with cisplatin for 1 h followed by culturing in Butyrate-containing medium for 1 and 2 h. The heterochromatic marks were determined through Western blotting. Relative amount of H3K9Me3 and HP-1α at various times post-cisplatin treatment were quantified relative to the respective untreated levels and normalized to Tubulin controls.